Eight months ago, Bayer and Johnson & Johnson (NYSE:JNJ) announced that the Food and Drug Administration had issued a complete response letter for their anticoagulant, Xarelto...
Keep Reading →
March 6 - News
Billionaire hedge fund manager David Tepper posted outstanding 2012 performance; he brought in $2.2 billion and returned some 30% for his hedge fund Appaloosa Management.
Keep Reading →
March 6 - Hedge Funds
Since everyone loves a winner, it's reasonable to assume that everyone hates a loser -- everyone but short sellers, at least. These contrarian investors bet that hot stocks...
Keep Reading →
March 6 - News
Are we beating up too much on Eli Lilly & Co.
Keep Reading →
March 6 - News
The market has been less than thrilled about an upcoming Supreme Court decision on the legality of the best-selling analytical test of Myriad Genetics, Inc. (NASDAQ:MYGN) .
Keep Reading →
March 5 - News
Do good things come in small packages for big pharma? Most of investors' attention is given to blockbuster drugs and drugs that have the potential to be blockbusters.
Keep Reading →
March 5 - News
Hello and welcome, readers. I’d like to issue an informal apology for the delay in writing in recent weeks.
Keep Reading →
March 4 - News
Mirror, mirror, on the wall, who's the frailest big pharma of all? The patent cliff has certainly taken its toll over the past couple of years, weakening several successful pharmaceutical...
Keep Reading →
March 1 - News
The rally from November lows has pushed many stocks toward rich P/E valuations, although the current spate of selling is doing its bit to bring these down.
Keep Reading →
February 27 - News
Are Bristol Myers Squibb Co. (NYSE:BMY) and Eli Lilly & Co.
Keep Reading →
February 25 - News
The Dow Jones Industrial Average breached the 4,000-point barrier for the first time in its history on Feb. 23, 1995, closing at 4,003.33.
Keep Reading →
February 23 - News
Irritable bowel syndrome has no organic cause and treating it usually depends on reducing symptoms of chronic abdominal pain, bloating, and gastric discomfort.
Keep Reading →
February 22 - News
After coming within striking distance of its all-time high, the Dow Jones Industrial Average pulled back sharply yesterday, dropping 108 points after the Fed's committee members...
Keep Reading →
February 22 - News
Analysts wonder if other drug companies will follow in the footsteps of Abbott Laboratories (NYSE:ABT) and spinoff different parts of their business.
Keep Reading →
February 21 - News
When the word "biotechnology" gets thrown around in the pharmaceutical industry, it often implies the biomanufacturing of biologic drugs, such as therapeutic proteins.
Keep Reading →
February 20 - News
Based on the aggregated intelligence of 180,000-plus investors participating in Motley Fool CAPS, the Fool's free investing community, biotechnology company NewLink Genetics Corp...
Keep Reading →
February 20 - News
Make no bones about it -- Zoetis Inc (NYSE:ZTS) is one expensive stock. It even might be the most expensive health-care stock for its size.
Keep Reading →
February 19 - News
It's now more than halfway through the period that Eli Lilly & Co. (NYSE:LLY) has called its "years YZ," a term describing the years spanning from 2011 to 2014.
Keep Reading →
February 19 - News
Pfizer Inc. (NYSE:PFE) faced a rough 2012 after Lipitor's loss of exclusivity in November 2011.
Keep Reading →
February 18 - News
Pfizer Inc. (NYSE:PFE) recently spun off animal health firm Zoetis Inc (NYSE:ZTS) in the form of an IPO.
Keep Reading →
February 15 - News
Some of the best-performing stocks over the past several decades boast long histories of paying dividends to shareholders. Moreover, if these stocks sell for an apparent discount...
Keep Reading →
February 14 - News
How much is trustworthiness actually worth? That somewhat strange thought entered my brain recently after reviewing the latest Harris Physician Pulse Survey.
Keep Reading →
February 13 - News
Lackluster trading was being blamed for the Dow Jones Industrial Average ticking down 21 points yesterday, gripped by ennui over both domestic and international financial woes...
Keep Reading →
February 12 - News
Regeneron Pharmaceuticals Inc (NASDAQ:REGN) said Monday that it got a notice from its partner Sanofi SA (NYSE:SNY) saying that the pharma intends to buy additional shares of the...
Keep Reading →
February 12 - News
Its narcolepsy drug Provigil saw generic competition from Par Pharmaceutical Companies, Inc. (NYSE:PRX) and Mylan Inc.
Keep Reading →
February 9 - News
One thing's for sure: You'll never discover truly great investments unless you actively look for them.
Keep Reading →
February 8 - News
It's not particularly surprising given that the drug failed a phase 3 trial in December, but it's still disappointing for a company that could really use a positive result.
Keep Reading →
February 7 - News
Looking for the hottest name in health care? Right now it's not big pharma nor even a hot biotech firm making waves on Wall Street; it's newly minted animal health firm Zoetis...
Keep Reading →
February 7 - News
With studies showing 33% of Americans with diabetes or pre-diabetes, it is obvious that the industry should be booming.
Keep Reading →
February 7 - News
Earnings season is a wrap for many of the brightest stars of the health care sector: Big pharma's big disappointments and successes are in the books, and investors are looking...
Keep Reading →
February 6 - News
Most hedge fund managers can only dream of breaking the “billion-dollar ceiling” of the big leagues, and they remain content with a critical mass of nine-figures or less.
Keep Reading →
January 23 - Hedge Funds
